The human immunodeficiency virus type-1 (HIV-1) envelope (Env) proteins that mediate membrane fusion represent a major target for the development of new AIDS therapies. Three classes of Env-mediated membrane fusion inhibitors have been described that specifically target the pre-hairpin intermediate conformation of gp41. Class 2 inhibitors bind to the C-terminal heptad repeat (C-HR) of gp41. The single example of a class 3 inhibitor targets the trimeric N-terminal heptad repeat (N-HR) of gp41 and has been postulated to sequestrate the N-HR of the pre-hairpin intermediate through the formation of fusion incompetent heterotrimers. Here, we show that N CCG -gp41, a class 2 inhibitor, and N36
Human immunodeficiency virus (HIV) envelope (Env)-mediated membrane fusion represents the first step of HIV-1 infection. Env comprises two non-covalently interacting proteins, gp120 and gp41, derived by proteolytic cleavage of gp160. [1] [2] [3] Fusion is triggered by the binding of gp120 on the virus with first CD4 and, subsequently, a chemokine receptor (CXCR4 or CCR5) on the surface of the target cell. These interactions result in a series of conformational changes that lead to the formation of a pre-hairpin (PHP) intermediate of gp41 [4] [5] [6] [7] [8] [9] in which the internal trimeric coiled-coil of N-helices (residues 542-591, comprising the N-heptad repeat or N-HR) is exposed and the N-terminal fusion peptide is inserted into the target membrane (Figure 1(a) ). gp41 is tethered to the viral membrane via a transmembrane domain that lies C-terminal to the C-heptad repeat (C-HR, residues 623-663). Subsequently, apposition of the viral and target cell membrane is driven by the formation of a trimer of hairpins in which the N-HR trimeric coiled-coil is surrounded by helices comprising the C-HR (Figure 1(a) , left-most diagram). 2, 10 The trimer of hairpins is the structure of the gp41 ectodomain that has been solved by both crystallography [11] [12] [13] and NMR. 14 Three classes of fusion inhibitors directed against the PHP conformation of gp41 have been described (Figure 1(a) ). Class I targets the N-HR trimeric coiledcoil. The first examples of class 1 inhibitors comprised peptides derived from the C-HR, such as C34 (residues 628-661) and T20 (residues 638-673, also known as Fuzeon™ and currently used in clinical practice). [15] [16] [17] More recently, both polyclonal 18 and monoclonal 19, 20 antibodies to the N-HR trimeric coiled-coil have been generated that also inhibit HIV-1 Env-mediated membrane fusion. Class 2 inhibitors target the C-HR. Examples of class 2 are various chimeric proteins in which the complete N-HR trimeric coiled-coil is exposed and stabilized by engineered disulfide bridges, 18, 21 such as N CCG -gp41
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E-mail addresses of the corresponding authors: caroleb@mail.nih.gov; mariusc@mail.nih.gov in which the trimeric coiled-coil of N-HR helices is fused in helical phase onto the minimal ectodomain core of gp41 and held together by engineered disulfide bridges. (c) Sequence of the N36 peptide comprising residues 546-581 of HIV-1 Env that constitute the N-HR, and the mutations introduced to generate the class 3 inhibitor N36
Mut(e.g) . (d) Helical wheel representation of the interaction between N-HR trimeric coiled-coil and a C-HR helix in the fusogenic trimer of hairpins; the main site of interaction occurs between positions e and g (red) of two N-HR helices and a and d (blue), respectively, of one C-HR helix. Mutation of the residues at positions e and g of the N-HR in N36
Mut(e,g) preclude any interaction with the C-HR. N CCG -gp41 was expressed and purified as described. 21 N36 Mut(e,g) , purchased from Biopeptide Co, Inc. (San Diego, CA), was synthesized on a solid phase support, purified by reverse phase high performance liquid chromatography, and verified for purity by mass spectrometry. N36 Mut(e,g) bears an acetyl group at the N terminus and an amide group at the C terminus. N CCG -gp41 is an obligate trimer, since the chains are held together by engineered intermolecular disulfide bridges. 21 
N36
Mut(e,g) forms a stable, monodisperse trimer in solution. 23 ( Figure 1(b) ) and N35 CCG -N13, as well as a construct known as 5-helix in which only one of the N-helices in the trimeric N-HR coiled-coil is exposed. 22 Finally, one example of a class 3 inhibitor has been described which also targets the N-HR trimeric coiled-coil but has been postulated to form fusion incompetent, inactive heterotrimers with the N-HR (Figure 1(a) ). 23 This particular inhibitor, known as N36 Mut(e,g) , was derived from the N-HR sequence comprising residues 546-581 of HIV-1 Env where all residues located at positions e and g of the helical wheel of the N-HR trimeric coiled-coil were mutated (Figure 1(c) ). Because these two positions are principal sites of interaction with the C-HR in the fusogenic trimer of haipins conformation of gp41 (Figure 1(d) ), N36 Mut (e,g) can no longer interact with the C-HR yet forms monodisperse trimers in solution.
Since the N-HR and C-HR represent non-overlapping sites in the PHP conformation of gp41, one might speculate that inhibitors that target these two regions might inhibit HIV-1 Env-mediated membrane fusion synergistically. However, class 1 and 2 inhibitors are mutually antagonistic, since they strongly interact with one another to form a sixhelix bundle analogous to the trimer of hairpins structure of the fusogenic form of gp41. 22 Class 2 and 3 inhibitors, however, do not interact with one another, and if the postulated mechanism of the class 3 inhibitor N36
Mut(e,g) is correct, synergistic inhibition by combination of class 2 and 3 inhibitors should occur. Here, we show, using two different assays with Env from several representative HIV-1 strains that the class 2 inhibitor NCCGgp41 and the class 3 inhibitor N36
Mut(e,g) do indeed Mut(e,g) in a 1:10 combination are shown in red. The experimental data (shown as filled circles) represent the averages of four to eight independent experiments and the standard deviations in the measurements are shown as vertical bars. The continuous curves represent best-fits to the experimental data using the simple activity relationship %fusion = 100/ (1+[inhibitor]/IC 50 ). The concentration of N36 Mut(e,g) is expressed as monomer, and the concentrations for the combination curves refer to the concentration of N CCG -gp41. The IC 50 values for N CCG -gp41 and N36 Mut(e,g) alone are summarized in Table 1 , and dose reduction and combination indices for both inhibitors acting in combination are listed in Table 2 . Experimental details for both assays are given in the footnotes to Table 1 . Although some curves may appear to exhibit a steeper concentration dependence than that predicted from the simple activity relationship, fitting the data to a more complex relationship is not warranted given the absence of a detailed mechanism, as well as uncertainties in the data. More importantly, the simple activity relationship fit provides an excellent estimate of the IC 50 . For example, the red curve in (a) obtained with a combination of N CCG -gp41 and N36
Mut(e,g) in a ratio of 1:10 can be fit perfectly to the expression % fusion = 100/(1+ [inhibitor]/K) n with a value of K=71(±8) nM (in N CCG gp41), and the Hill coefficient n set equal to 2. The relationship between K and IC 50 is given by 34 IC 50 =( n √2-1)K yielding a calculated value of 29(±3) nM for the IC 50 ; this compares to the near identical value of 27(±6) nM for the IC 50 obtained by fitting the same data to the simple activity relationship (i.e. n=1).
inhibit Env-mediated membrane fusion in a synergistic manner.
To test the hypothesis that class 2 and 3 inhibitors may act synergistically to inhibit viral fusion we tested the respective, representative inhibitors, N CCG -gp41 and N36
Mut(e,g) , individually and in constant ratio combinations against several representative HIV-1 strains (two R4 strains, LAV and HXB2, and one R5 strain, SF162). In addition, to address potential differences that may arise between different fusion assays, the same inhibitors or combinations thereof were tested in two different fusion assays. The first assay was a quantitative vaccinia virus-based reporter gene assay 21, [24] [25] [26] for cell-cell fusion that employs robust cell surface expression of HIV-1 Env on effector cells and constitutive cell surface expression of membrane-bound CD4 and chemokine co-receptors on target TZM-b1 cells. The total duration of the fusion assay is ∼2.5 h. The second assay, which is ∼48 h in duration, was a neutralization assay employing Envpseudo-typed virus and TZM-b1 target cells. 27, 28 Representative data for each of these assays is shown in Figure 2 and the complete data are summarized in Tables 1 and 2 . Mut(e,g) are 150(±16) nM and 753(±152) nM, respectively, in the fusion assay, and 85(±18) nM and 7399(±713) nM, respectively, in the HXB2 Env-pseudo-typed virus neutralization assay. When N CCG -gp41 and N36
Mut(e,g) are used in combination in a ratio of 1:10, the IC 50 (expressed in concentration of N CCG -gp41) value is reduced to 27 (±6) nM and 43(±7) nM in the cell fusion and Envpseudo-typed virus neutralization assays, respectively ( Figure 2) .
The formalism used to ascertain the effects of inhibitors in combination has been described in detail by Chou & Talalay. 29 In the context of the present assays, the dose reduction index (DRI x ) of a fusion inhibitor x in the presence of a fusion inhibitor y is given by DRI x = IC 50,x /IC 50,x (y), where IC 50,x and IC 50,x (y) are the IC 50 values of inhibitor x alone and in the presence of inhibitor y, respectively. Assuming simple ligand binding, the c It is worth noting that the IC 50 for inhibition of LAV Envmediated cell fusion by N CCG -gp41 in the fusion assay employed here that makes use of CD4 expressed on the surface of the target cells is about five-to seven fold higher than that in the equivalent fusion assay using soluble CD4 and CD4-negative target cells. 21 This is not unexpected, since the fusion activity in the soluble CD4 activated system is lower than that in the membrane-bound activated system.
25
d Env-pseudo-typed virus stocks were prepared as described. 27, 28 Exponentially dividing 293T cells were transfected using the FUGENE6 transfection kit (Roche, Nutley, NJ) with the Env-deficient HIV-1 expression plasmid SG3Δenv and the appropriate Env-expressing plasmid in the ratios corresponding approximately to the ratio of the vector sizes (16 μg total DNA per T-150 culture flask). Culture supernatants were collected two days post-transfection, filtered through 0.45 μm filter and stored at -86°C. Env-pseudo-typed virus neutralization assays were performed essentially as described. 27, 28 Serial dilutions of inhibitor solution were added to Env-pseudo-typed virus in DMEM 10% FCS (50 μl), followed by trypsinized TZM-bl indicator cells (10,000 cells in 20 μl of the same medium). Plates were incubated at 37°C overnight, after which a further 150 μl of growth medium was added. Approximately 48 h post-infection cells were lysed and luciferase activity was measured using the BrightGlo luciferase assay kit (Promega, Madison, WI) with a Wallac 1450 MicroBeta TriLux liquid scintillation and luminescence counter (Perkin-Elmer Life Sciences, Downers Grove, IL). Env-pseudo-typed virus stocks were diluted to yield ∼100-fold increase of luminescence over the uninfected cells background. The effect of virus input was examined in preliminary experiments, and IC 50 values were found to remain stable using virus inputs producing between 20 and 200-fold increases of luminescence over the background (between 2×10 3 and 2 × 10 4 LCPS units, respectively). e ND, no inhibition of fusion detected. effect of two inhibitors in combination is quantified by the combination index (CI), given by:
(Note that the last term, which makes only a small contribution to the CI, accounts for the state in which both inhibitors are bound). A value of CI = 1 is indicative of a purely additive effect of the two inhibitors; that is the inhibition curve of the two inhibitors in combination is simply given by the summation of the two inhibitor curves alone, taking into account the different concentrations of the two inhibitors employed. A value of CI > 1 indicates that the two inhibitors are mutually antagonistic; that is the effect of two inhibitors in combination is smaller than expected for an additive effect. A value of CI < 1 indicates that the two inhibitors act synergistically; that is the inhibitory effect is greater than one would predict for a purely additive effect. Typically, a value of CI of 0.3-0.7 is considered to represent significant synergism, 0.70-0.85 moderate synergism, and 0.85-0.90 slight synergism. 30 For optimal observation of synergy, the ratio of inhibitor concentrations should be approximately comparable to the ratio of the IC 50 values of the inhibitors alone.
The data in Table 2 summarize the DRI and CI values obtained for a series of constant ratio combinations of N CCG -gp41 and N36
Mut(e,g) ranging from 1:5 to 1:30. For N CCG -gp41 alone, the IC 50 values were lower in the Env-pseudo-typed neutralization assay than in the cell fusion assay for both X4 and R5 strains; for N36
Mut(e,g) alone the opposite trend was observed (Table 1 ). Despite the fact that the IC 50 values for N CCG -gp41 and N36
Mut(e,g) alone display a range of values depending on both the strain of HIV-1 Env employed and the nature of the assay, in every case, clear cut synergistic inhibition of Env-mediated fusion by these two inhibitors in combination is apparent with CI values ranging from 0.4 to 0.6 ( Table  2 ). The mean value of the CI obtained from all the assays is 0.52 with a standard error of 0.03. In one case, namely inhibition of SF162 Env-mediated membrane fusion observed in the Env-pseudotyped virus neutralization assay, a CI value could not be determined, since no inhibition of fusion could be detected for N36
Mut(e,g) alone (Table 1) . Nevertheless, even in this instance clear evidence for synergism was obtained, since the combination of N CCG -gp41 and N36
Mut(e,g) resulted in a significant reduction in the IC 50 of N CCG -gp41 (DRI NCCG-gp41 ∼1.7; Table 2 ).
Control experiments (data not shown) were also carried out using combinations of N CCG -gp41 and cyanovirin-N, a fusion inhibitor that targets highmannose oligosaccharides on the surface of gp120. 31 In this instance, the effect of these two inhibitors, at a ratio of cyanovirin to N CCG -gp41 of 1:10 was purely additive in the cell fusion assay with a CI value of 0.97 ± 0.07. This result is expected, since the two inhibitors act on discrete, unrelated targets of HIV-1 Env that are relevant at different steps during the fusion process.
The synergistic inhibition of HIV-1 Env-mediated membrane fusion by N CCG -gp41 and N36 Mut(e,g) has mechanistic, as well as obvious potential practical applications. In the context of inhibition of fusion by class 2 inhibitors, such as N CCG -gp41, Mut(e,g) alone. b The combination index is given by equation (1) in the text. c ND, not determined. Since no detectable inhibition of fusion could be obtained with N36
Mut(e,g) alone in the virus neutralization assay employing SF162 HIV-1 Env, the dose reduction index for N36
Mut(e,g) as well as the overall combination index cannot be determined. Nevertheless, the presence of synergy between N CCG -gp41 and N36
Mut(e,g) is evident, since the IC 50 for N CCG -gp41 is significantly reduced in the presence of N36 Mut(e,g) . the binding of the inhibitor to the C-HR of the PHP conformation of gp41 must compete with the binding of the C-HR of gp41 to the N-HR of the same molecule that results in the formation of the fusogenic trimer of hairpins configuration. In the intact system the formation of the latter can be considered irreversible, since it is accompanied by concomitant apposition of the viral and cell membranes and subsequent fusion. By forming heterotrimers between N36
Mut(e,g) and the N-HR of the PHP of gp41 it is logical that (a) the overall apparent strength of the interaction between the N-HR and C-HR of gp41 will be significantly diminished, since the population of native state in which one C-HR interacts with two adjacent N-HRs in the trimer of hairpins will be reduced as a result of heterotrimer formation (cf Figure 1(a) ), and (b) the probability of forming a trimer of hairpins will also be significantly reduced owing to the presence of heterotrimers, which are in relatively slow equilibrium with the homotrimeric coiled-coil of N-HR helices (cf. Figure 1(a) ). Concomitantly, the sequestration of the N-HR of the PHP of gp41 into fusion incompetent heterotrimers by N36 Mut(e,g) will enhance the probability of complex formation between N CCG -gp41 and the C-HR of the PHP of gp41. Dimitrov et al. 32 recently showed that treatment of Env-expressing cell with N36
Mut(e,g) reduced the binding of the monoclonal antibody NC-1 which recognizes the N-HR trimer of gp41 and enhanced binding to the class 2 fusion inhibitor 5-helix. Both observations are consistent with the mechanism of N36
Mut(e,g) forming stable heterotrimers with wild-type N-HR of Env. 23 Thus, the results presented here further substantiate the mechanism of action of class 3 inhibitors postulated by Bewley et al. 23 From a purely practical perspective, the data presented here suggest that combination therapy with class 2 and 3 inhibitors may represent a useful avenue for future development and implementation of novel anti-fusion HIV therapies.
